TORC1 inhibition enhances immune function and reduces infections in the elderly
Top Cited Papers
- 11 July 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (449), eaaq1564
- https://doi.org/10.1126/scitranslmed.aaq1564
Abstract
Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation. In addition, we observed an up-regulation of antiviral gene expression and an improvement in the response to influenza vaccination in this treatment group. Thus, selective TORC1 inhibition has the potential to improve immune function and reduce infections in the elderly.Funding Information
- Novartis
This publication has 23 references indexed in Scilit:
- Regulation of mTOR Activity in Snell Dwarf and GH Receptor Gene-Disrupted MiceEndocrinology, 2014
- Depletion of Rictor, an essential protein component of m TORC 2, decreases male lifespanAging Cell, 2014
- The Hallmarks of AgingCell, 2013
- mTOR is a key modulator of ageing and age-related diseaseNature, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from LongevityScience, 2012
- mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem CellsScience Signaling, 2009
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2PLoS Biology, 2009
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K MutationsCancer Research, 2008
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMolecular Cancer Therapeutics, 2008